Antitumor efficacy
Evaluate single agents, combinations, and reference arms in project-matched human tumor cell line xenografts.
ONCOLOGY MODEL
Cell Line-Derived Xenograft (CDX) Models
Human tumor cell line-derived xenograft platforms span hematologic and solid-tumor indications including lung, breast, colorectal, pancreatic, gastric, liver, renal, prostate, and brain cancers.
Cell line, tumor indication, host background, implantation design, dosing schedule, and downstream readouts are aligned during technical review.
MODEL OVERVIEW
Broad CDX coverage for defined oncology pharmacology questions.
Documented partner portfolios include a wide range of human tumor cell lines for subcutaneous xenograft studies, enabling model selection around tumor type, molecular context, compound mechanism, and intended efficacy or translational readouts.
Therapeutic areaOncology
SpeciesMouse
Model formatHuman tumor cell line xenograft
Typical useEfficacy, PK/PD, Biomarkers
TYPICAL APPLICATIONS
What this model can support.
Tumor-type selection
Select models across documented hematologic and solid-tumor indications according to target biology and program context.
Resistance-focused studies
Drug-resistant cell-line models can be reviewed where the mechanism or development question requires a resistance context.
PK/PD integration
Integrate systemic exposure, tumor exposure, pharmacodynamic markers, and tissue collection when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Tumor response
Protocol-defined tumor growth, inhibition, regression, or other efficacy readouts.
Tolerability
Body weight, clinical observations, and dosing tolerance during the efficacy phase.
PK & exposure
Plasma, tumor, or selected tissue exposure when incorporated into the study design.
Tissue analysis
Protocol-defined histology, IHC, molecular, or biomarker analysis on collected tissues.
Final cell line availability, host background, implantation design, cohort size, endpoints, and study timeline are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- Tumor indication and cell line
- Molecular profile or resistance context
- Host background and implantation format
- Growth characteristics and study window
- Dose route, schedule, and formulation
- Required tissue, biomarker, and PK/PD outputs
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a CDX study.Required fields are marked with an asterisk(*).